Johnson & Johnson (NYSE:JNJ) Shares Sold by Private Advisor Group LLC

Private Advisor Group LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 41.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 254,360 shares of the company's stock after selling 181,089 shares during the quarter. Private Advisor Group LLC's holdings in Johnson & Johnson were worth $42,183,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. WealthTrak Capital Management LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at about $29,000. Conquis Financial LLC acquired a new stake in Johnson & Johnson in the 4th quarter worth about $33,000. Bernard Wealth Management Corp. bought a new stake in Johnson & Johnson in the 4th quarter valued at about $36,000. Finally, Runnymede Capital Advisors Inc. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $38,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 0.4%

Johnson & Johnson stock traded up $0.67 during trading hours on Friday, hitting $163.65. 9,764,459 shares of the stock traded hands, compared to its average volume of 8,141,137. The firm's 50-day moving average price is $154.29 and its two-hundred day moving average price is $155.05. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The company has a market cap of $393.75 billion, a PE ratio of 17.50, a PEG ratio of 2.19 and a beta of 0.41. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same period last year, the company earned $2.82 EPS. Johnson & Johnson's revenue for the quarter was up 5.8% on a year-over-year basis. On average, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.18%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is 55.61%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on JNJ. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday. Royal Bank Of Canada lifted their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a report on Thursday. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Barclays lifted their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday. Finally, Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and an average target price of $172.87.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.